Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Brain Cancer Specialty Channel

FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
News
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
04/25/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the...
04/25/2024
Oncology
Test Your Knowledge
Quiz: Is Large-Scale Outcome Data Currently Flawed in Brain Cancer Research?
01/12/2021
True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently lacking.
True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently lacking.
True or False: Although the...
01/12/2021
Oncology
News
Postsurgery HSRT Safer Than Whole-Brain RT for Brain Metastases
12/28/2020
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of...
12/28/2020
Oncology
News
No Survival Advantage With Whole-Brain RT vs Stereotactic Radiosurgery for SCLC
08/24/2020
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC,...
08/24/2020
Oncology
News
Pembrolizumab Safe, Active for Certain Patients With NSCLC and Brain Metastases
05/14/2020
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active...
05/14/2020
Oncology
News
Higher Risk for Brain Metastases With Twice vs Once Daily Radiotherapy After Irradiation for SCLC
06/28/2019
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received...
06/28/2019
Oncology
News
Brain Tumor Therapy Tied to Severe Sensorineural Hearing Loss, Difficulty Reading
06/07/2019
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with...
06/07/2019
Oncology
News
Cranial Irradiation Reduces Long-term Risk for Brain Metastasis in NSCLC
04/02/2019
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a...
04/02/2019
Oncology
News
Neratinib–Capecitabine Combo Active Against Breast Cancer Brain Metastases
03/19/2019
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support...
03/19/2019
Oncology

Advertisement

News

FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
News
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
04/25/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the...
04/25/2024
Oncology
News
Postsurgery HSRT Safer Than Whole-Brain RT for Brain Metastases
12/28/2020
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of...
12/28/2020
Oncology
News
No Survival Advantage With Whole-Brain RT vs Stereotactic Radiosurgery for SCLC
08/24/2020
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC,...
08/24/2020
Oncology
News
Pembrolizumab Safe, Active for Certain Patients With NSCLC and Brain Metastases
05/14/2020
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active...
05/14/2020
Oncology
News
Higher Risk for Brain Metastases With Twice vs Once Daily Radiotherapy After Irradiation for SCLC
06/28/2019
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received...
06/28/2019
Oncology
News
Brain Tumor Therapy Tied to Severe Sensorineural Hearing Loss, Difficulty Reading
06/07/2019
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with...
06/07/2019
Oncology
News
Cranial Irradiation Reduces Long-term Risk for Brain Metastasis in NSCLC
04/02/2019
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a...
04/02/2019
Oncology
News
Neratinib–Capecitabine Combo Active Against Breast Cancer Brain Metastases
03/19/2019
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support...
03/19/2019
Oncology

Interactive Features

Test Your Knowledge
Quiz: Is Large-Scale Outcome Data Currently Flawed in Brain Cancer Research?
01/12/2021
True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently lacking.
True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently lacking.
True or False: Although the...
01/12/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
News
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
04/25/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the...
04/25/2024
Oncology
News
Postsurgery HSRT Safer Than Whole-Brain RT for Brain Metastases
12/28/2020
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of...
12/28/2020
Oncology
News
No Survival Advantage With Whole-Brain RT vs Stereotactic Radiosurgery for SCLC
08/24/2020
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC,...
08/24/2020
Oncology
News
Pembrolizumab Safe, Active for Certain Patients With NSCLC and Brain Metastases
05/14/2020
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active...
05/14/2020
Oncology
News
Higher Risk for Brain Metastases With Twice vs Once Daily Radiotherapy After Irradiation for SCLC
06/28/2019
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received...
06/28/2019
Oncology
News
Brain Tumor Therapy Tied to Severe Sensorineural Hearing Loss, Difficulty Reading
06/07/2019
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with...
06/07/2019
Oncology
News
Cranial Irradiation Reduces Long-term Risk for Brain Metastasis in NSCLC
04/02/2019
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a...
04/02/2019
Oncology
News
Neratinib–Capecitabine Combo Active Against Breast Cancer Brain Metastases
03/19/2019
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support...
03/19/2019
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement